Venkatesan Jay's Form 4/A amendment
AmendedElicio Therapeutics, Inc. (ELTX) · filed May 27, 2022
- Accession no.
- 0001601485-22-000045
- Filed
- May 27, 2022
- Trade date
- Feb 9, 2021
- Filing delay
- 472 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Feb 11, 2021
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.55M. It was filed 472 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Venkatesan JayCIK 0001413350 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2021 | Common Stock | XIn-the-money exerciseAcquired | +396,329 | $6.43 | +$2,548,395.47 | 1,598,440 | Direct | |
| Feb 9, 2021 | Common Stock | SSaleDisposed | −159,177 | $16.00 | −$2,546,832 | 1,367,263 | Direct | |
| Feb 9, 2021 | Common Stock | CConversionAcquired | +262 | $11.57 | +$3,031.34 | 1,439,525 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2021 | Common Stock | XIn-the-money exerciseDisposed | −396,329 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,329 shares of the Issuer's common stock for $6.43 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 159,177 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 237,152 shares of common stock.
Remarks
President and Chief Executive Officer and Director